“What 1Day Sooner would do with your marginal dollar: Hepatitis C Vaccine Advocacy” by 1daysooner, Josh Morrison
Description
1Day Sooner advocates on behalf of people who join medical studies for altruistic reasons. We focus particularly on “challenge studies,” where participants are exposed to pathogens to develop vaccines and learn about infectious disease. We work at three levels: trials, technologies, and policies. Our best analysis of our knowable causal impact through summer of 2024 can be found here. We believe we have a strong opportunity to generate millions of dollars in funding for hepatitis C vaccine development for $50-200K.
This year, we expanded our trials work by launching our “Cooperative Participant Organization,” which provides support to trial teams working on high-value infectious disease research. This has expanded our trial support work from our previous focus on hepatitis C challenge studies to cover enteric, parasitic, and other hepatic trials.
But expanding our trials work has opened up a gap in advancing hepatitis C vaccine technologies, since the team that previously covered both trials and hepatitis C vaccines now have a wider range of responsibilities. We have an opportunity that we think could lead to >$10M in funding from the NIH for hepatitis C vaccine development (including hepatitis C challenge studies), but we currently do not have the staffing to [...]
---
First published:
November 19th, 2025
---
Narrated by TYPE III AUDIO.
United States
